• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Absci (ABSI) On Positive ABS 201 Phase 1 Data And The Valuation Debate

    Simply Wall St·11/01/2026 07:34:03
    語音播報

    Absci (ABSI) put fresh clinical data on the table, reporting positive interim Phase 1 results for its hair loss candidate ABS-201, including an estimated half-life of at least 65 days that could support less frequent dosing.

    Absci shares pulled back around 8% in the latest session to about $11.13 after a strong run, with a 7 day share price return of 21.24% and a year to date share price gain of 208.31% suggesting that momentum has been building despite a recent wobble.

    Scan other early-stage biotech stories moving on fresh data by reviewing our hand-picked list of 34 healthcare AI stocks alongside Absci.

    Bulls see Absci’s AI platform plus fresh ABS-201 data as the start of a bigger franchise. Bears point to early-stage risk and heavy losses. Which side does the current valuation lean toward?

    Most Popular Narrative: 25% Undervalued

    Absci last closed at $11.13, while the most widely followed narrative anchors on a fair value of $14.90. The gap hinges on how much faith you put in ABS-201 and the broader pipeline.

    Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months positions Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.

    Disciplined capital allocation away from ABS-101 and into ABS-201, combined with a cash runway into the first half of 2028, allows Absci to progress multiple high value shots on goal. This improves the risk reward profile of future earnings relative to the current valuation.

    See why 16 investors see Absci as 25% undervalued.

    Result: Fair Value of $14.90 (UNDERVALUED)

    Still, the whole Absci story leans heavily on ABS-201 delivering clean efficacy and safety data, and on management successfully landing the AI partnership deals that analysts are counting on.

    Find out about the key risks to this Absci narrative.

    Next Steps

    If this mix of optimism and caution around Absci feels familiar, consider taking time while the details are fresh to weigh both sides in light of the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Absci?

    If Absci has your attention, do not leave potential opportunities on the table. Use the Simply Wall Street Screener to quickly surface stocks that better fit your risk and return preferences.